Clonoseq testing for VISN 1
Ended Awarded Last action
- Contract number
- 36C24124N0570
- Awardee
-
Adaptive Biotechnologies Corporation UEI DMW5BNQ331K9
- Awarding agency
-
Veterans Integrated Service Network 1
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $11,700
Award facts
- Contract value 100% obligated
- $11,700.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- West Roxbury, MA 02132, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$154,000 | |
| Original award | $165,700 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 1 (VISN 1) awarded a firm fixed-price call order valued at $11,700 to Adaptive Biotechnologies Corporation for ClonoSEQ testing services. This award, dated July 15, 2024, represents a call against Adaptive's existing Blanket Purchase Agreement (BPA) with VISN 1, which carries a total ceiling value of $828,750 over a five-year period ending in July 2027. The work will be performed at the VA Medical Center in West Roxbury, Massachusetts. ClonoSEQ is a specialized minimal residual disease testing service that uses advanced genomic sequencing technology to detect and monitor cancer cell populations, supporting clinical diagnostics and treatment monitoring across VA medical facilities in the New England region. No set-aside designation was applied to this award, indicating open competition under the BPA vehicle.
The award includes a deobligation of excess funds in the amount of $154,000, reflecting fund management adjustments against the broader agreement. Adaptive Biotechnologies, headquartered in Seattle, Washington, is a commercial provider of immune-driven medical services with extensive experience delivering specialized immunosequencing and genomic testing capabilities to federal agencies, including the VA, National Institutes of Health, and Defense Health Agency. Under the VISN 1 BPA, Adaptive has received multiple call orders totaling over $330,000 for testing services at VA locations including Boston, West Haven, and Seattle, demonstrating the contractor's established role in supporting VA healthcare missions through advanced diagnostic testing.
Quick answers
Who was awarded contract 36C24124N0570?
36C24124N0570 was awarded to Adaptive Biotechnologies Corporation by Veterans Integrated Service Network 1 (Veterans Health Administration) on July 15, 2024.
How much is contract 36C24124N0570 worth?
The government has obligated $11,700 on 36C24124N0570.
Is contract 36C24124N0570 an order under another contract?
Yes. 36C24124N0570 is a BPA call under 36C24122A0124, a blanket purchase agreement.
Was contract 36C24124N0570 competed?
The extent of competition for 36C24124N0570 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award